These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28961190)

  • 1. Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era.
    Chupradit K; Moonmuang S; Nangola S; Kitidee K; Yasamut U; Mougel M; Tayapiwatana C
    Viruses; 2017 Sep; 9(10):. PubMed ID: 28961190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
    Hale M; Mesojednik T; Romano Ibarra GS; Sahni J; Bernard A; Sommer K; Scharenberg AM; Rawlings DJ; Wagner TA
    Mol Ther; 2017 Mar; 25(3):570-579. PubMed ID: 28143740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
    Sherpa C; Le Grice SFJ
    Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Closing the door to human immunodeficiency virus.
    Kang Y; Guo J; Chen Z
    Protein Cell; 2013 Feb; 4(2):86-102. PubMed ID: 23479426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1.
    Stratov I; Dale CJ; Chea S; McCluskey J; Kent SJ
    J Virol; 2005 Jun; 79(12):7728-37. PubMed ID: 15919925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
    Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
    Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
    Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Immune Interventions for an HIV-1 Cure.
    Perreau M; Banga R; Pantaleo G
    Trends Mol Med; 2017 Oct; 23(10):945-961. PubMed ID: 28890135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals.
    Mayr L; Su B; Moog C
    Curr Opin HIV AIDS; 2017 May; 12(3):209-215. PubMed ID: 28422785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systems serology for evaluation of HIV vaccine trials.
    Ackerman ME; Barouch DH; Alter G
    Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy and therapeutic vaccines in HIV infection.
    García F; Ruiz L; López-Bernaldo de Quirós JC; Moreno S; Domingo P
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():84-104. PubMed ID: 16373008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutics to Treat HIV in the Central Nervous System.
    Kapoor A; Tan CS
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):499-506. PubMed ID: 32671567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.